<DOC>
	<DOCNO>NCT02940886</DOCNO>
	<brief_summary>Evaluation safety efficacy iron isomaltoside compare iron sucrose subject suffer IDA</brief_summary>
	<brief_title>Iron Isomaltoside Iron Sucrose Treatment Iron Deficiency Anemia ( IDA )</brief_title>
	<detailed_description>IDA highly prevalent subject cancer gastrointestinal disease inflammatory bowel disease , menstruate pregnant woman , subject undergone bariatric procedure . IDA substantial medical quality life ( QoL ) burden subject , treatment subject include control bleed replenish lose iron . This study design evaluate safety efficacy iron isomaltoside compare iron sucrose subject suffer IDA .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Inclusion criterion include : 1 . Men woman ≥ 18 year 2 . Subjects IDA cause different etiology 3 . Subjects intolerance oral iron therapy need rapid repletion iron store : 4 . Hb ≤ 10 g/dL 5 . TSAT &lt; 20 % 6 . Sferritin &lt; 100 ng/mL 7 . Willingness participate signing informed consent form Exclusion Criteria include : 1 . Anemia predominantly cause factor IDA 2 . Hemochromatosis iron storage disorder 3 . Previous serious hypersensitivity reaction IV iron compound 4 . Erythropoiesis stimulate agent ( ESA ) treatment 5 . Prior screen trial period ; treat red blood cell transfusion , radiotherapy , and/or chemotherapy 6 . Will require surgical procedure necessitate general anesthesia prior screen trial period 7 . Decompensated liver cirrhosis active hepatitis 8 . Required dialysis treatment CKD 9 . Alcohol drug abuse within past 6 month 10 . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>